Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: van dorst eb, van der putten h, van beurden m. J Clin Oncol. 2007 Jan 20;25(3):301-7. doi: 10.1200/JCO.2006.07.4922. J Clin Oncol. 2007. PMID: 17235045
Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM, Beurden MV, Kieffer JM, Bleiker EMA, Valdimarsdottir HB, Massuger LFAG, Mourits MJE, Gaarenstroom KN, van Dorst EBL, van der Putten HWHM, Aaronson NK. Vermeulen RFM, et al. Among authors: van der putten hwhm. Eur J Cancer. 2017 Oct;84:159-167. doi: 10.1016/j.ejca.2017.07.018. Epub 2017 Sep 4. Eur J Cancer. 2017. PMID: 28818705
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: van dorst eb, van der putten h, van der velden k, van beurden m. J Clin Oncol. 2005 Oct 1;23(28):6890-8. doi: 10.1200/JCO.2005.02.626. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129845 Free article.
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: van dorst eb, van der putten h, van der velden k, van beurden m. J Clin Oncol. 2006 Aug 1;24(22):3576-82. doi: 10.1200/JCO.2005.05.1896. J Clin Oncol. 2006. PMID: 16877724 Free article.
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, Van der Velden J, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Van der Zee AG, et al. Among authors: van dorst eb, van der velden j, van der putten h. J Clin Oncol. 2008 Feb 20;26(6):884-9. doi: 10.1200/JCO.2007.14.0566. J Clin Oncol. 2008. PMID: 18281661 Free article. Clinical Trial.
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study.
Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, van Dorst EB, van der Velden J, Hermans RH, van der Putten HW, Drouin P, Runnebaum IB, Sluiter WJ, van der Zee AG. Oonk MH, et al. Among authors: van dorst eb, van hemel bm, van der putten hw, van der velden j, van der zee ag. Lancet Oncol. 2010 Jul;11(7):646-52. doi: 10.1016/S1470-2045(10)70104-2. Epub 2010 May 25. Lancet Oncol. 2010. PMID: 20537946
MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer.
Vos MC, Hollemans E, Ezendam N, Feijen H, Boll D, Pijlman B, van der Putten H, Klinkhamer P, van Kuppevelt TH, van der Wurff AA, Massuger LF. Vos MC, et al. Among authors: van der putten h. J Ovarian Res. 2016 Sep 2;9(1):53. doi: 10.1186/s13048-016-0262-7. J Ovarian Res. 2016. PMID: 27590006 Free PMC article.
Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival.
Vos MC, van Tilborg A, Brands WJ, Boll D, van Hamont D, van der Putten H, Pijlman B, van der Wurff AAM, van Kuppevelt TH, Massuger LFAG. Vos MC, et al. Among authors: van der putten h. Cancer Biomark. 2019;25(3):233-241. doi: 10.3233/CBM-181826. Cancer Biomark. 2019. PMID: 31282404
Adnexal masses in pregnancy.
Hermans RH, Fischer DC, van der Putten HW, van de Putte G, Einzmann T, Vos MC, Kieback DG. Hermans RH, et al. Among authors: van der putten hw, van de putte g. Onkologie. 2003 Apr;26(2):167-72. doi: 10.1159/000069838. Onkologie. 2003. PMID: 12771526
126 results